Etifoxine, a TSPO Ligand, Worsens Hepatitis C-Related Insulin Resistance but Relieves Lipid Accumulation

Yu Min Lin, Hung Yu Sun, Wen Tai Chiu, Hui Chen Su, Yu Chieh Chien, Heng Ai Chang, Lee Won Chong, Hung Chuen Chang, Kung Chia Young, Chyi Huey Bai, Chiung Wen Tsao

研究成果: 雜誌貢獻文章

摘要

Etifoxine, an 18 kDa translocator protein (TSPO) agonist for the treatment of anxiety disorders in clinic, may be able to cause acute liver injury or cytolytic hepatitis. TSPO has been demonstrated to participate in inflammatory responses in infective diseases as well as to modulate glucose and lipid homeostasis. Hepatitis C virus (HCV) infection disrupts glucose and lipid homoeostasis, leading to insulin resistance (IR). Whether TSPO affects the HCV-induced IR remains unclear. Here, we found that the administration of etifoxine increased the TSPO protein expression and recovered the HCV-mediated lower mitochondrial membrane potential (MMP) without affecting HCV infection. Moreover, etifoxine reversed the HCV-induced lipid accumulation by modulating the expressions of sterol regulatory element-binding protein-1 and apolipoprotein J. On the other hand, in infected cells pretreated with etifoxine, the insulin-mediated insulin receptor substrate-1/Akt signals, forkhead box protein O1 translocation, and glucose uptake were blocked. Taken together, our results pointed out that etifoxine relieved the HCV-retarded MMP and reduced the lipid accumulation but deteriorated the HCV-induced IR by interfering with insulin signal molecules.

原文英語
文章編號3102414
期刊BioMed Research International
2019
DOIs
出版狀態已發佈 - 一月 1 2019

指紋

Hepatitis C
Viruses
Hepacivirus
Insulin Resistance
Insulin
Ligands
Lipids
Proteins
Mitochondrial Membrane Potential
Virus Diseases
Glucose
Homeostasis
Clusterin
Sterol Regulatory Element Binding Protein 1
Forkhead Transcription Factors
Membranes
Insulin Receptor Substrate Proteins
Protein Transport
etifoxine
Anxiety Disorders

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

引用此文

Lin, Y. M., Sun, H. Y., Chiu, W. T., Su, H. C., Chien, Y. C., Chang, H. A., ... Tsao, C. W. (2019). Etifoxine, a TSPO Ligand, Worsens Hepatitis C-Related Insulin Resistance but Relieves Lipid Accumulation. BioMed Research International, 2019, [3102414]. https://doi.org/10.1155/2019/3102414

Etifoxine, a TSPO Ligand, Worsens Hepatitis C-Related Insulin Resistance but Relieves Lipid Accumulation. / Lin, Yu Min; Sun, Hung Yu; Chiu, Wen Tai; Su, Hui Chen; Chien, Yu Chieh; Chang, Heng Ai; Chong, Lee Won; Chang, Hung Chuen; Young, Kung Chia; Bai, Chyi Huey; Tsao, Chiung Wen.

於: BioMed Research International, 卷 2019, 3102414, 01.01.2019.

研究成果: 雜誌貢獻文章

Lin, YM, Sun, HY, Chiu, WT, Su, HC, Chien, YC, Chang, HA, Chong, LW, Chang, HC, Young, KC, Bai, CH & Tsao, CW 2019, 'Etifoxine, a TSPO Ligand, Worsens Hepatitis C-Related Insulin Resistance but Relieves Lipid Accumulation', BioMed Research International, 卷 2019, 3102414. https://doi.org/10.1155/2019/3102414
Lin, Yu Min ; Sun, Hung Yu ; Chiu, Wen Tai ; Su, Hui Chen ; Chien, Yu Chieh ; Chang, Heng Ai ; Chong, Lee Won ; Chang, Hung Chuen ; Young, Kung Chia ; Bai, Chyi Huey ; Tsao, Chiung Wen. / Etifoxine, a TSPO Ligand, Worsens Hepatitis C-Related Insulin Resistance but Relieves Lipid Accumulation. 於: BioMed Research International. 2019 ; 卷 2019.
@article{78917c922b4948eaafcc2fb5e4a419c8,
title = "Etifoxine, a TSPO Ligand, Worsens Hepatitis C-Related Insulin Resistance but Relieves Lipid Accumulation",
abstract = "Etifoxine, an 18 kDa translocator protein (TSPO) agonist for the treatment of anxiety disorders in clinic, may be able to cause acute liver injury or cytolytic hepatitis. TSPO has been demonstrated to participate in inflammatory responses in infective diseases as well as to modulate glucose and lipid homeostasis. Hepatitis C virus (HCV) infection disrupts glucose and lipid homoeostasis, leading to insulin resistance (IR). Whether TSPO affects the HCV-induced IR remains unclear. Here, we found that the administration of etifoxine increased the TSPO protein expression and recovered the HCV-mediated lower mitochondrial membrane potential (MMP) without affecting HCV infection. Moreover, etifoxine reversed the HCV-induced lipid accumulation by modulating the expressions of sterol regulatory element-binding protein-1 and apolipoprotein J. On the other hand, in infected cells pretreated with etifoxine, the insulin-mediated insulin receptor substrate-1/Akt signals, forkhead box protein O1 translocation, and glucose uptake were blocked. Taken together, our results pointed out that etifoxine relieved the HCV-retarded MMP and reduced the lipid accumulation but deteriorated the HCV-induced IR by interfering with insulin signal molecules.",
author = "Lin, {Yu Min} and Sun, {Hung Yu} and Chiu, {Wen Tai} and Su, {Hui Chen} and Chien, {Yu Chieh} and Chang, {Heng Ai} and Chong, {Lee Won} and Chang, {Hung Chuen} and Young, {Kung Chia} and Bai, {Chyi Huey} and Tsao, {Chiung Wen}",
year = "2019",
month = "1",
day = "1",
doi = "10.1155/2019/3102414",
language = "English",
volume = "2019",
journal = "BioMed Research International",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Etifoxine, a TSPO Ligand, Worsens Hepatitis C-Related Insulin Resistance but Relieves Lipid Accumulation

AU - Lin, Yu Min

AU - Sun, Hung Yu

AU - Chiu, Wen Tai

AU - Su, Hui Chen

AU - Chien, Yu Chieh

AU - Chang, Heng Ai

AU - Chong, Lee Won

AU - Chang, Hung Chuen

AU - Young, Kung Chia

AU - Bai, Chyi Huey

AU - Tsao, Chiung Wen

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Etifoxine, an 18 kDa translocator protein (TSPO) agonist for the treatment of anxiety disorders in clinic, may be able to cause acute liver injury or cytolytic hepatitis. TSPO has been demonstrated to participate in inflammatory responses in infective diseases as well as to modulate glucose and lipid homeostasis. Hepatitis C virus (HCV) infection disrupts glucose and lipid homoeostasis, leading to insulin resistance (IR). Whether TSPO affects the HCV-induced IR remains unclear. Here, we found that the administration of etifoxine increased the TSPO protein expression and recovered the HCV-mediated lower mitochondrial membrane potential (MMP) without affecting HCV infection. Moreover, etifoxine reversed the HCV-induced lipid accumulation by modulating the expressions of sterol regulatory element-binding protein-1 and apolipoprotein J. On the other hand, in infected cells pretreated with etifoxine, the insulin-mediated insulin receptor substrate-1/Akt signals, forkhead box protein O1 translocation, and glucose uptake were blocked. Taken together, our results pointed out that etifoxine relieved the HCV-retarded MMP and reduced the lipid accumulation but deteriorated the HCV-induced IR by interfering with insulin signal molecules.

AB - Etifoxine, an 18 kDa translocator protein (TSPO) agonist for the treatment of anxiety disorders in clinic, may be able to cause acute liver injury or cytolytic hepatitis. TSPO has been demonstrated to participate in inflammatory responses in infective diseases as well as to modulate glucose and lipid homeostasis. Hepatitis C virus (HCV) infection disrupts glucose and lipid homoeostasis, leading to insulin resistance (IR). Whether TSPO affects the HCV-induced IR remains unclear. Here, we found that the administration of etifoxine increased the TSPO protein expression and recovered the HCV-mediated lower mitochondrial membrane potential (MMP) without affecting HCV infection. Moreover, etifoxine reversed the HCV-induced lipid accumulation by modulating the expressions of sterol regulatory element-binding protein-1 and apolipoprotein J. On the other hand, in infected cells pretreated with etifoxine, the insulin-mediated insulin receptor substrate-1/Akt signals, forkhead box protein O1 translocation, and glucose uptake were blocked. Taken together, our results pointed out that etifoxine relieved the HCV-retarded MMP and reduced the lipid accumulation but deteriorated the HCV-induced IR by interfering with insulin signal molecules.

UR - http://www.scopus.com/inward/record.url?scp=85063472607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063472607&partnerID=8YFLogxK

U2 - 10.1155/2019/3102414

DO - 10.1155/2019/3102414

M3 - Article

VL - 2019

JO - BioMed Research International

JF - BioMed Research International

SN - 2314-6133

M1 - 3102414

ER -